The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells

References

• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–2132.
   PubMed Web of Science ®Google Scholar
• Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9:52
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–1634.
   PubMed Web of Science ®Google Scholar
• Sanchez L, Wang Y, Siegel DS, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016;9:51.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao N, Xu W, et al. Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma. J Hematol Oncol. 2016;9:54.
   PubMed Web of Science ®Google Scholar
• De Vos J, Jourdan M, Tarte K, et al. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol. 2000;109:823–828.
   PubMed Web of Science ®Google Scholar
• Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol. 1999;29:3945–3950.
   PubMed Web of Science ®Google Scholar
• Li J, Favata M, Kelley JA, et al. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia. 2010;12:28–38.
   PubMed Web of Science ®Google Scholar
• Burger R, Le Gouill S, Tai YT, et al. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther. 2009;8:26–35.
   PubMed Web of Science ®Google Scholar
• Pedranzini L, Dechow T, Berishaj M, et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. 2006;66:9714–9721.
   PubMed Web of Science ®Google Scholar
• Yang Y, Groshong JS, Matta H, et al. Constitutive NF-kappaB activation confers interleukin 6 (IL6) independence and resistance to dexamethasone and Janus kinase inhibitor INCB018424 in murine plasmacytoma cells. J Biol Chem. 2011;286:27988–27997.
   PubMed Web of Science ®Google Scholar
• Rawat R, Rainey GJ, Thompson CD, et al. Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas. Blood. 2000;96:3514–3521.
   PubMed Web of Science ®Google Scholar
• Gan ZY, Fitter S, Vandyke K, et al. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. Eur J Haematol. 2015;94:343–354.
   PubMed Web of Science ®Google Scholar
• Baumann P, Schneider L, Mandl-Weber S, et al. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012;23:131–138.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Hideshima T, Fulciniti M, et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010;116:1460–1468.
   PubMed Web of Science ®Google Scholar
• Glassford J, Kassen D, Quinn J, et al. Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations. Blood Cancer J. 2012;2:e50.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. Oncogene. 2014;33:1890–1903.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM, Zhan F, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296–303.
   PubMed Web of Science ®Google Scholar
• Lesage D, Troussard X, Sola B. The enigmatic role of cyclin D1 in multiple myeloma. Int J Cancer. 2005;115:171–176.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev. 2003;194:96–104.
   PubMed Web of Science ®Google Scholar
• Scuto A, Krejci P, Popplewell L, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia. 2011;25:538–550.
   PubMed Web of Science ®Google Scholar
• Hurt EM, Wiestner A, Rosenwald A, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5:191–199.
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Sakai A, Tsuyama N, et al. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma. Int J Oncol. 2008;33:1201–1213.
   PubMed Web of Science ®Google Scholar
• Janssen JW, Vaandrager JW, Heuser T, et al. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood. 2000;95:2691–2698.
   PubMed Web of Science ®Google Scholar
• Park GB, Song H, Kim YS, et al. Cell cycle arrest induced by engagement of B7-H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines. Immunology. 2009;128:360–368.
   PubMed Web of Science ®Google Scholar
• Iriyama N, Hatta Y, Takei M. ETV6/ARG oncoprotein confers autonomous cell growth by enhancing c-Myc expression via signal transducer and activator of transcription 5 activation in the acute promyelocytic leukemia cell line HT93A. Leuk Lymphoma. 2015;56:2416–2423.
   PubMed Web of Science ®Google Scholar
• Iriyama N, Hatta Y, Takei M. Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes. Cancer Med. 2016;5:3223–3234.
   PubMed Web of Science ®Google Scholar
• Iriyama N, Yuan B, Yoshino Y, et al. Enhancement of differentiation induction and upregulation of CCAAT/enhancer-binding proteins and PU.1 in NB4 cells treated with combination of ATRA and valproic acid. Int J Oncol.2014;44:865–873.
   PubMed Web of Science ®Google Scholar
• Uchino Y, Iriyama N, Hatta Y, et al. Granulocyte colony-stimulating factor potentiates all-trans retinoic acid-induced granulocytic differentiation in acute promyelocytic leukemia cell line HT93A. Cancer Cell Int. 2015;15:30.
   PubMed Web of Science ®Google Scholar
• Iriyama N, Yuan B, Hatta Y, et al. Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation. Cancer Cell Int. 2016;16:37.
   PubMed Web of Science ®Google Scholar
• Moriya S, Komatsu S, Yamasaki K, et al. Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress-mediated cell death in multiple myeloma cells. Int J Oncol. 2015;46:474–486.
   PubMed Web of Science ®Google Scholar
• Moriya S, Che XF, Komatsu S, et al. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. Int J Oncol. 2013;42:1541–1550.
   PubMed Web of Science ®Google Scholar
• Sridharan S, Jain K, Basu A. Regulation of autophagy by kinases. Cancers (Basel). 2011;3:2630–2654.
   PubMedGoogle Scholar
• Capparelli C, Chiavarina B, Whitaker-Menezes D, et al. CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, “fueling” tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle. 2012;11:3599–3610.
   PubMed Web of Science ®Google Scholar
• Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6:463–477.
   PubMed Web of Science ®Google Scholar
• Hoang B, Benavides A, Shi Y, et al. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther. 2009;8:1974–1984.
   PubMed Web of Science ®Google Scholar
• Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest. 2011;121:3554–3563.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Kikukawa Y, Takeya M, et al. Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol. 2010;37:815–820.
   PubMed Web of Science ®Google Scholar
• Maiuri MC, Zalckvar E, Kimchi A, et al. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol. 2007;8:741–752.
   PubMed Web of Science ®Google Scholar
• Shen S, Kepp O, Kroemer G. The end of autophagic cell death? Autophagy. 2012;8:1–3.
   PubMed Web of Science ®Google Scholar
• Maltese WA, Overmeyer JH. Methuosis: nonapoptotic cell death associated with vacuolization of macropinosome and endosome compartments. Am J Pathol. 2014;184:1630–1642.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016;6:740–753.
   PubMed Web of Science ®Google Scholar
• Vidula N, Rugo HS. Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast cancer: a review of preclinical and clinical data. Clin Breast Cancer. 2016;16:8–17.
   PubMed Web of Science ®Google Scholar
• DiPippo AJ, Patel NK, Barnett CM. Cyclin-dependent kinase inhibitors for the treatment of breast cancer: past, present, and future. Pharmacotherapy. 2016;36:652–667.
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Bisi JE, Strum JC, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012;104:476–487.
   PubMed Web of Science ®Google Scholar
• Menu E, Garcia J, Huang X, et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res. 2008;68:5519–5523.
   PubMed Web of Science ®Google Scholar
• Baughn LB, Di Liberto M, Wu K, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 2006;66:7661–7667.
   PubMed Web of Science ®Google Scholar